A phytochemical comparison of saw palmetto products using gas chromatography and H nuclear magnetic resonance spectroscopy metabolomic profiling by Booker, A et al.
A phytochemical comparison of saw palmetto products
using gas chromatography and 1H nuclear magnetic
resonance spectroscopy metabolomic profiling
Anthony Bookera, Andy Sutera,b, Ana Krnjicb, Brigitte Strasselb, Mire Zlohc*, Mazlina Saidc† and
Michael Heinricha,d
aCentre for Pharmacognosy and Phytotherapy, cUCL School of Pharmacy, University of London, London, UK, bA.Vogel, Bioforce AG, Roggwil,
Switzerland and dDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
Keywords
fatty acids; gas chromatography; 1H nuclear
magnetic resonance spectroscopy;
metabolomics; saw palmetto
Correspondence
Michael Heinrich, Centre for Pharmacognosy
and Phytotherapy, UCL School of Pharmacy,
University of London, London, UK.
E-mail: m.heinrich@ucl.ac.uk
Received June 21, 2013
Accepted November 16, 2013
doi: 10.1111/jphp.12198
Present address: *Department of Pharmacy,
University of Hertfordshire, College Lane,
Hatfield AL10 9AB, UK and †Centre for Drug
and Herbal Research, Universiti Kebangsaan
Malaysia, Jalan Raja Muda Abdul Aziz, 50300
Kuala Lumpur, Malaysia
Abstract
Objectives Preparations containing saw palmetto berries are used in the treat-
ment of benign prostatic hyperplasia (BPH). There are many products on the
market, and relatively little is known about their chemical variability and specifi-
cally the composition and quality of different saw palmetto products notwith-
standing that in 2000, an international consultation paper from the major
urological associations from the five continents on treatments for BPH demanded
further research on this topic. Here, we compare two analytical approaches and
characterise 57 different saw palmetto products.
Methods An established method – gas chromatography – was used for the quan-
tification of nine fatty acids, while a novel approach of metabolomic profiling
using 1H nuclear magnetic resonance (NMR) spectroscopy was used as a finger-
printing tool to assess the overall composition of the extracts.
Key findings The phytochemical analysis determining the fatty acids showed a
high level of heterogeneity of the different products in the total amount and of
nine single fatty acids. A robust and reproducible 1H NMR spectroscopy method
was established, and the results showed that it was possible to statistically differen-
tiate between saw palmetto products that had been extracted under different con-
ditions but not between products that used a similar extraction method. Principal
component analysis was able to determine those products that had significantly
different metabolites.
Conclusions The metabolomic approach developed offers novel opportunities
for quality control along the value chain of saw palmetto and needs to be followed
further, as with this method, the complexity of a herbal extract can be better
assessed than with the analysis of a single group of constituents.
Introduction
Saw palmetto (Serenoa repens (W.Bartram) Small
(Arecaceae.syn.: Sabal serrulata (Michx.) Schult.f.)) is a
small, low-growing, dwarf-palm tree, native to South-
eastern North America, particularly Florida. The American
Indians of this region used the berries medicinally and as a
food source, long before the arrival of the Europeans.
Preparations of saw palmetto are made of the ripe, partially
dried olive size berries, and they were used traditionally for
a wide range of indication like bronchitis, common colds,
for the treatment of genito-urinary disorders of men and
women, and as a sexual stimulant. In the United States, the
plant gained recognition as an official remedy in 1906 being
first mentioned in the US Pharmacopoeia,[1] followed in
1926 with the inclusion in the US National Formulary.[2]
Since the 1990s, saw palmetto has been one of the top 10
top-selling herbal medicines in the United States, and the
worldwide turnover of Serenoa preparations is likely to be
700 million dollars per annum.[3] In Europe, the extract of
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saw palmetto is the herbal medicine most frequently used
for the treatment of the urological symptoms caused by
benign prostatic hyperplasia (BPH), and the evidence from
over 35 clinical trials supports the use of standardised saw
palmetto extract for the treatment of lower urinary symp-
toms associated with BPH. Treatment with the extract has
shown increased peak urine flow, and decreased nocturia,
without increasing serum prostate-specific antigen (PSA)
levels.[4] In a pilot trial, we could show that saw palmetto
also had a positive effect on concomitant sexual dysfunc-
tions in BPH patients.[5] The dose recommended for a
lipophilic saw palmetto extract is 320 mg daily administered
once daily. Usually, the extract contains 70–95% free fatty
acids like capric, caproic, caprylic, lauric, myristic, oleic,
linoleic, linolenic, stearic and palmitic acids[6] with their
ethyl esters and glycerides that occur most likely during
the extraction process. Further phytosterols like β-sitosterol
and β-sitosterol 3-O-D-glucoside, campesterol, and
stigmasterol[7] are found with about 0.1% of the total mass
of the berries. Other constituents are carbohydrates such as
mannitol and polysaccharides with galactose and arabinose,
triterpenes, aromatic acids like ferulic and vanillic acid,
β-carotens, the vitamine E derivates γ-tocopherol and
δ-tocopherols,[6] mono-acyl glycerides like 1-monolaurin
and 1-monomyristin,[8] and the monoamine tyramine.[9]
A combination of several factors has been implicated as
potential mode of action for saw palmetto. The main prop-
erties to consider are its anti-androgenic, pro-apoptotic and
anti-inflammatory effects.[10] Fatty acids are considered to
be key active constituents, and Bayne et al. reported its
effectiveness as a dual inhibitor of 5α-reductase activity in
the prostate gland.[11]
There are many extracts on the market obtained using
different extraction processes resulting in a lack of equiva-
lence of these products. One study examining the content of
saw palmetto in six commercial preparations compared
with the amounts as stated on labels reported a −97% to
+140% difference compared with the label claim. Half of
the samples tested contained less than 25% of the stated
amount.[12] Furthermore, Habib and Wyllie commented
that the potency of tested extracts appeared to be signifi-
cantly different with respect to their isoenzyme inhibition
and suggested that only extracts with evidence of activity
and clinical efficiency should be considered for the treat-
ment of BPH.[13] The only official quality marker so far for
saw palmetto preparations is to be found in the European
Pharmacopoeia that requires lauric acid to be at least 20%
of the total fatty acid.[14]
To gain a better understanding of the chemical variability
of these products, we analysed 57 different products
from nine countries that contain saw palmetto as
monopreparations or as a part of multicomponent supple-
ments. All test products are used for treatment of BPH
symptoms and were analysed either with gas chromatogra-
phy or 1H nuclear magnetic resonance (NMR) spectroscopy
with subsequent principal component analysis (PCA).
Consequently, the goal of this novel comparative study
was to evaluate the quality of saw palmetto preparations by
using fatty acids as quality markers and, for the first time,
assess if 1H NMR spectroscopy and PCA are suitable, robust
and fast methods for quality evaluation of these products.
Metabolomics and principal
component analysis
Metabolomics is the term used for the comprehensive, non-
biased, high-throughput analyses of complex metabolite
mixtures such as those typically seen in plant extracts.
Achieving a broad overview of metabolic composition is
very complex and requires the establishment of a fully inte-
grated approach for the optimisation of sample extraction,
metabolite separation/detection/identification, automated
data gathering, processing and analysis, and quantifi-
cation.[15] Metabolomics has become a well-recognised
method for the study of all types of organisms and comple-
ments the data obtained by the other ‘omics’-technologies:
genomics, transcriptomics and proteomics.[16] One of the
main problems associated with metabolomics is that the
metabolome consists of a wide range of compounds at very
different concentrations and with different polarities. At
present, there is no single solvent capable of solubilising the
whole range of chemical constituents. The choice of extrac-
tion solvent is thus limiting the view on the metabolome. In
general, metabolomic studies should be designed to detect
as many metabolites as possible in an organism[17] In this
study, plant extracts are the focus and so the metabolomic
profile of the plant will have already been simplified. As this
study is concerned with the analysis and quality of herbal
medicinal products, this simplification fits in with the aims
and objectives of the study, however, if we chose to look
at the saw palmetto plant, the extraction steps would need
to be optimised to attempt to extract the full range of
metabolites.
NMR is an effective tool for the quality control of
medicinal plants or herbal medicinal products[18] The
advantages of NMR spectroscopy over other techniques
such as mass spectroscopy (MS) for metabolomics applica-
tions include the relative ease of sample preparation, non-
destructive analysis, potential to identify a broad range of
compounds, enhanced capacity for definitive chemical
compound identification, and provision of structural infor-
mation for unknown entities.[19] 1H NMR spectroscopy is an
ideal tool for large-scale plant metabolomics data collec-
tion. Multivariate or pattern recognition techniques such as
PCA are valuable techniques for the analysis of data
obtained by NMR spectroscopy. In combination with PCA,
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NMR spectroscopy has been applied to the metabolomics
profiling of plants and herbal medicines.[20]
PCA is a math-based method of reorganising informa-
tion found in a data set of samples. It can be used when the
set contains information from only a few variables, but it is
most useful when there are large numbers of variables, as in
spectroscopic data. What PCA does is to discover new vari-
ables, called ‘principal components’, which account for the
main variability of the data.[21] Data are represented in ‘n’
dimensional space, where n is the number of variables, and
is reduced into a few principal components, which are
descriptive dimensions that describe the maximum vari-
ation within the data. The principal components can be dis-
played in a graphical fashion as a ‘scores’ plot. This plot is
useful for observing any groupings in the data set and, in
addition, will highlight outliers that may be due to errors in
sample preparation or instrumentation parameters. PCA
models are constructed using all the samples in the study.
Coefficients by which the original variables must be multi-
plied to obtain the PC are called ‘loadings’. The numerical
value of a loading of a given variable on a PC shows how
much the variable has in common with that component.
Thus, for NMR data, ‘loading plots’ can be used to detect
the spectral areas (metabolites) responsible for the separa-
tion in the data.[22]
Materials and Methods
Test samples
Fifty-seven samples were obtained from retail outlets or
pharmacies from Canada, Finland, Germany, the Nether-
lands, the United Kingdom, South Korea, Spain, Switzerland
and the United States. Of these products that were soft
gel or hard gel capsules, tablets or tinctures, 29 were
monopreparations containing only saw palmetto, and 28
were combined with other constituents such as vitamins,
herbal extracts or minerals (labelled ‘combi-preparations’).
Thirty-four products were tested with 1H NMR spectros-
copy, 46 with gas chromatography and 26 preparations in
both analyses. For the determination of the fatty acids with
gas chromatography, 19 mono and 27 combi were analysed.
The extracts were in the majority not well-declared on the
packages or package leaflets as they were sold as food sup-
plements and were not registered, so only for 12 products
proper drug- solvent (extractant) ratio and the extractant
were available. The declarations given showed that the
majority of the saw palmetto extracts were lipophilic, at
least one (SP14) contained also crude saw palmetto berry
powder. A detailed description of all the test items including
which analysis, gas chromatography (GC) or NMR, was
carried out with which product is given as supplementary
material (published online).
Determination of fatty acids with gas
chromatography
The method is based on the esterification and subsequent
separation and analysis using gas chromatography calcu-
lated against heptadecanic acid as internal standard. This is
a modified method of the German Society for Fat Science
for fatty acid methyl esters, where in the end, the free fatty
acids are determined.[23]
For each preparation, 1 g of the capsule content or of the
tablets was extracted for 45 min with 70-ml hexane together
with 5-ml heptadecanic acid. The extraction solution was
concentrated to ca. 25 ml on the rotary evaporator and
dried with sodium sulfate.
Six millilitres of 2% methanolic sodium hydroxide solu-
tion were added to the residue and heated to the boiling
point for 10 min, then 5-ml boron trifluoride-methanol
complex were added and the whole mixture was boiled for
another 2 min. Finally, 20-ml heptane were added, stirred
and the mixture cooled down.
Afterwards, saturated sodium chloride solution was added
until the heptane phase ascended into the flask neck. About
1 ml of the resulting heptane phase was dried in a centrifuge
tube with water-free sodium sulfate; the clear yellowish green
solution was used for the GC-flame ionisation detector. The
analysis was performed twice for each test preparation with a
gas chromatograph (Trace GC ultra, Thermo Electron Corpo-
ration, Waltham, MA, USA) using an Optima 5 capillary
column containing 5% Phenyl and 95% Methylpolysiloxan,
25 m × 0.32 mm iD with 0.25 μm layer thickness.
The column was held isothermally for 1 min at 100°C,
then the temperature was programmed to increase at a rate
of 5°C/min to 190°C where it was kept for 5 min. The injec-
tor was set to 250°C, and an amount of 1-μl solution was
injected using the split mode with hydrogen as carrier gas at
a constant pressure of 40 kPa.
The system suitability was given when in the
chromatogram, the resolution between the main peak lauric
acid and myristic acid amounted to at last 10. The single
fatty acids that were assigned according to the retention
time of the peaks and were calculated in reference to the
area of heptadecanoic acid. The areas were integrated by
using Chromcard software. The methods precision is 0.9%,
and the correlation in linearity is 0.998.
1H NMR spectroscopy
Solvents, reagents and chemicals
Deuterated methanol-d4 (99.8%) lot no. 10C-522,
Tetramethylsilane (99.9%) lot no. 81–140 and deuterated
chloroform-d with added 0.05% v/v Tetramethylsilane lot
no. 9F-330 were purchased from Cambridge Isotope
Laboratories, Inc., Andover, MA, USA.
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Reference standards: Caproic acid ethyl ester, lot no.
S28172-020; oleic acid, lot no. 098 K5216, and stigmasterol,
lot no. 53F0322 were purchased from Sigma-Aldrich
Chemicals, St Louis, MO, USA.
Apparatus and instrumentation
Bruker Avance NMR Spectrophotometer (500 MHz) with
Topspin software version 1.3
AMIX Bruker Biospin multivariate analysis software version
3.0
Soft Independent Modeling of Class Analogy Software
(SIMCA) Version 13.0
Ependorff Minispin plus centrifuge, model 5453, Serial no.
0031564
Fisher brand ultrasound bath, model D-78224, serial no.
004472044
Rotamixer, rotary mixer, serial no. 8011
Gilson micro-pipettes 200ul, serial no.AC55298 and 1000ul,
serial no. AD63010 (calibrated 15.6.10)
Reaction tubes, 1.5 ml eppendorf supplied by Griener Bio-
One, Germany
Wilmad LabGlass NMR sample tubes, 5 mm economy,
7″Length, 100 MHz
Sample preparation
The method for the extraction of plant samples was devel-
oped from a method described by Frederich et al.[24] Initial
experiments were carried out using deuterated methanol-d4,
but it was found that many of the soft gel capsule extracts did
not dissolve satisfactorily in deuterated methanol-d4, and so
the solvent was changed to deuterated chloroform-d contain-
ing 0.05% tetramethylsilane (TMS). The solubility of the saw
palmetto soft gel capsule extract products was improved
using this solvent, and so two experiments were carried out.
Deuterated chloroform-d was identified as the solvent of
choice for the 1H NMR spectroscopy analysis of soft gel
capsule extracts, and deuterated methanol-d4 was used for
the crude powders and powder extracts.
Methanol soluble: Ten brands of single ingredient crude
powder, powder extract or tablet, and four brands of
multicomponent powders were tested.
Chloroform soluble: Thirteen brands of single ingredient
soft gel capsule extract and six brands of multicomponent
soft gel capsule extract were tested.
Approximately 150 mg of sample was accurately weighed
and transferred to a 1.5-ml eppendorf reaction tube,
1.0 ml of deuterated methanol-d4 or 1.0 ml of deuterated
chloroform-d containing 0.05% TMS was added. The
mixture was mixed on a rotary mixer for 10 s and sonicated
in an ultrasound bath for 30 min, followed by further
mixing on a rotary mixer. The solutions were centrifuged
for 5 min at 13 000 rpm. Six hundred microlitres of the
supernatant was added to a 5 mm diameter NMR spectros-
copy tube, and the samples were submitted for 1H NMR
spectroscopy analysis.
NMR spectroscopy measurements
The 1H NMR spectra were acquired using 500 MHz NMR
Bruker Avance spectrometer (Bruker BioSpin GmbH,
Rheinstetten, Germany) equipped with a multinuclear
probe head with z-gradient. The acquisition parameters
were: size of the spectra 64 k data points, line broadening
factor = 0.16 Hz, pulse width = 30 degrees and the relaxa-
tion delay d1 = 1 s. TOPSPIN version 1.3 software was used
for spectra acquisition and processing. The NMR was
set up for the analysis applying diffusion-edited 1H
NMRspectroscopy with suppression of ethanol and water
signals. The scans were locked at zero on the TMS peak.
Two hundred fifty-six scans was the number of scans
chosen for optimum resolution of peaks.
Statistical analysis
All spectra were phase-corrected, baseline-corrected, zeroed
to the TMS peak and transferred to AMIX (Analysis of Mix-
tures software v3.0, BrukerBiospin, Rheinstetten, Germany).
Before multivariate analysis, the spectra were reduced in
complexity by using the ‘bucketing’ function found in
AMIX to generate a number of integrated regions of the
data set. The spectra in the range of 0.0–10.0 ppm were
divided into 251 regions (buckets) of 0.04 ppm, and the
signal intensity in each area was integrated. Water signals
(4.50–5.00 ppm), residual proton signals corresponding to
MeOD (3.24–3.35 ppm), CDCl3 (7.1–7.4 ppm) and TMS
internal standard (−0.1 to 0.1 ppm) were excluded. These
data were imported to Microsoft EXCEL where the samples
were relabelled SP1 to SP37. The data were then imported
into the SIMCA Version 13.0 for PCA analysis. The data
were normalised using peak range normalisation.
Results and Discussion
Determination of fatty acids using GC
As these products are used in a therapeutic and disease-
preventive context, it is essential to analyse the products
from a perspective of daily therapeutic doses. To gain an
understanding of the composition of the products in the
context of their use as health-care products for the 46 prod-
ucts, we calculated the amount of fatty acids per day as the
sum of the most prominent fatty acids in saw palmetto,
lauric acid, capric acid, caprylic acid, myristic acid, palmitic
acid, linolenic acid, oleic/linoleic acid and stearic acid for
the lowest daily dosage as given by the manufacturer on the
package. We chose the lowest daily dosage because for some
products, there was a range in the dosage given, for
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example, two to six tablets per day, and the manufacturer of
the product considers this lowest dosage still to be thera-
peutically beneficial.
The daily dosages were heterogenous. For 20 products, it
was one unit per day, for 21 products twice and for one
preparation thrice daily; for three products, there was a 4×
daily and for one product even a 6× daily recommended
intake. Also, the amount of saw palmetto extract declared
for one tablet or capsule varied widely from 2.5 to 500 mg
per unit.
The analysis showed that there was great heterogenicity
between the products in the amount of fatty acids per day
(Figure 1) for the lowest daily dosage per product. The con-
centrations were in the range between 8.43 mg for the
product with the lowest daily amount of fatty acids and
1473 mg for the preparation with the highest value.
Mono and combination products differed slightly in the
average when looking at all-test items regarding the content
of fatty acids, but the combinations displayed a larger
variability. Products containing only saw palmetto had
an average daily dose of 230.5 ± 127.2 mg fatty acids
per day (mean ± standard deviation) with values rang-
ing from 30.89 to 1473.2 mg, combination products of
261.0 ± 247.5 mg with a range from 8.34 to 1173.02 mg
daily. The corresponding median values were 271.9 mg for
monopreparations and 239.3 mg/day for combinations,
respectively.
The differences in the daily amount of fatty acids per
product were more pronounced when looking at the
country of origin. The monopreparations from Switzerland
and South Korea all showed similar concentrations, while
the highest dosed US American product contained 2.7 times
the amount of the preparation with the lowest dose (a
Spanish product); for Canada, this ratio was 3.0, and for
Spain even 13.3.
For the monopreparations, we observed a large difference
between the amount of saw palmetto extract as declared on
the package and the measured amount of fatty acids. The
differences ranged from about one-tenth fatty acids up to
4.6 more fatty acids compared with the declaration given on
the package (Table 1).
Usually lipophilic saw palmetto extracts contain 70–95%
fatty acids (Table 1).
The composition of the saw palmetto mono-extracts was
in the majority comparable (Figure 2). The percentage of
the nine different single fatty acids was more or less compa-
rable in about 14 of the monopreparations; the samples
SP54, 34, 53, 8 and 37 differed the most from the average
values.
Saw palmetto fruits contain high amounts of oleic and
lauric acid; each is present with around 30–40% of the total
fatty acids,[25] and the previously mentioned 14 preparations
showed high concentrations of lauric and oleic/linoleic acid
as well. The amount of 20% lauric acid per saw palmetto
extract as demanded in the European Pharmacopeia[14] was
reached by all but four monopreparations. Three of these
four products, SP34, SP54 and SP8, had larger amounts of
oleic and linoleic acid and one item, SP37, contained a very
high concentration of linolenic acid that is unusual for saw
palmetto berries and gave rise to a suspected adulteration
with another plant oil. This conclusion was supported by
the 1H NMR spectroscopy analysis (see later)
On average, the combination products showed a different
pattern compared with saw palmetto preparation. They
contained less lauric, oleic/linoleic and myristic acid but
higher concentrations of palmitic, linolenic and stearic acid.
1H NMR spectroscopy and PCA
A PCA model of the 1H NMR spectroscopy fingerprints of
the investigated products in deuterated chloroform-d
showed that most clustered in one well-defined region with
SP26, SP34 and SP37 being different from the main group
(Scores plot, Figure 3). The scores plot is a graphical repre-
sentation of the variance in chemical composition of the
different products. The three extracts were yellow-orange in
colour rather than the brown-green colour of the European
extracts. On examination of the product specification, it
was discovered that SP26 utilises super critical fluid extrac-
tion, SP34 has the added ingredients of extra virgin olive
oil, glycerin, carob and zinc oxide, and SP37 has the added
ingredients of soya bean oil and glycerin that could explain
the differences (Figure 3).
The loadings plot (Figure 4) shows the chemical shifts
that are responsible for the main variances in the soft gel
capsule extract samples. It can be seen that the major vari-
ances occur in the fatty acid regions, including oleic acid
(5.3–5.5 ppm) and also in the esterified region, where
caproic acid ethyl ester has been identified (from reference
standards) (4.1–4.2 ppm). It is probable that the extraction
methods used for these samples have increased the quan-
tities of fatty acids, and methyl and ethyl esters in these
products. The comparatively larger intensities of peaks
observed in these regions may be attributable to the use of
super fluid critical extraction or the addition of olive oil,
soya bean oil and glycerin.
SP12 was shown to be the most distinctive sample
(Figure 5); it was also the only one that was found to be an
n-hexane, liposterolic extract with the added ingredient of
polyoxethylene glycol (Figure 5). It is highly probable that
the variance observed was due to a combination of these
factors. Examination of the spectra of SP12, as in previous
experiments, showed a very large peak between 3.62 and
3.64 ppm. This peak was absent from any other of the
spectra and is suspected to be caused by the polyoxethylene
glycol (from NMR spectroscopy reference data). SP6 also
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Figure 1 Daily dose of fatty acids based on the lowest daily dosage given on the package for each product analysed. White bars indicate
monopreparations containing only saw palmetto as active constituent, dark bars combination preparations that in addition contain other ingredients
like vitamins or other herbal extracts. For each product, the country and the specimen number are given.
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Figure 2 The percentage of each single fatty acid measured for each product. The bar ‘Ø registered’ shows the value of all registered products, ‘Ø
mono’ the average values of all 19 monopreparations and ‘Ø combi’ the average values of all the 27 combination products. For each product, the
country and the specimen number are given.
Table 1 Characteristics of the monopreparations comparing the difference between the amount of saw palmetto extract as declared on the
package and the measured concentration of total fatty acids assuming the extract would consist 100% of fatty acids
Sample
number Country
Tablet (t) or hard gel
capsule (hc) or soft
gel capsule (sc)
Amount of saw palmetto
extract per unit (mg) as
declared on package
Total fatty acids
(mg) per unit measured
Difference declaration
versus measurement (%)
SP8 ES t 80 368.3 460.4
SP37 CA sc 80 253.06 316.3
SP34 US sc 160 378.2 236.4
SP53 US sc 160 354.61 221.6
SP54 US sc 320 444.31 138.8
SP36 CH sc 160 151.56 94.7
SP33 FI sc 320 290.24 90.7
SP49 US sc 320 285.68 89.3
SP35 CH sc 320 281.34 87.9
SP27 CH sc 320 274.53 85.8
SP31 CH sc 320 274.45 85.8
SP32 KR sc 320 271.9 85.0
SP30 CH sc 320 271.82 84.9
SP29 KR sc 320 237.74 74.3
SP12 ES hc 160 55.68 34.8
SP45 CA hc 350 51.01 14.6
SP14 UK hc 300 34.5 11.5
SP13 CA hc 500 56.8 11.4
SP11 UK hc 450* 44.57 9.9
*Also contains saw palmetto powder.
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shows some variation with the main group, and examina-
tion of the spectra shows a marked difference in peak posi-
tions and intensities in 3.4–3.8 region, a doublet peak at
5.4 ppm, and a large singlet peak at 9.54 ppm, indicating
the possible presence of an aldehyde.
It was possible to identify variances in multicomponent
formulae from pure saw palmetto soft gel capsule extracts
(Figure 6). The combination products were not well-
grouped, but this was to be expected as they were all made
up of different herbal ingredients. There was good grouping
of samples of extracts to the centre and left in the scores
plot, whereas all of the multicomponent formulae were
placed in the right-hand quadrants. The principal axes of
the scores plot represents the first and second PC scores,
and so the relative variation of each component can be
observed in each quadrant, e.g. scores in the upper right
quadrant represent relalatively high concentrations of both
PC1 and PC2.
Currently, this phytochemical analysis of 57 commercial
preparations from nine different countries is the most com-
prehensive investigation of saw palmetto products carried
out so far.
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Figure 3 Ellipse scores plot showing soft gel extracts in chloroform-d (SP25 – SP37).
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With the standard GC method, nine fatty acids were ana-
lysed, which comprise more than 95% of the fatty acids of
saw palmetto berries.[25] The analysis showed they varied
widely with a factor of about 177 between the minimum
and maximum concentration in mono products and 38 for
combinations.
In general, saw palmetto monographs recommend a daily
dose of 320 mg lipophilic berry extract with 70–95% fatty
acids.[6,26] When this daily dosage of 224–304 mg fatty acids
is taken as an acceptable quality standard, then only nine
monopreparations were in this range. Sixteen combinations
and five saw palmetto only brands displayed higher daily
fatty acid values, 5 mono and 11 combination items lower
quantities.
A too low daily amount of fatty acids may lead to a lack
of efficacy, too high concentrations may not results in
immediate health hazards as these fatty acids have a very
low toxicity and higher dosages of saw palmetto extract for
example were still very well-tolerated,[27] but it makes it
impossible to compare these products in terms of their effi-
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Figure 5 Ellipse scores plot based on NMR spectroscopy data for saw palmetto crude powders and powder extracts in methanol-d4 (SP6–SP15)
versus multicombination formulae in methanol-d4 (SP1, SP22, SP23, SP24).
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cacy and evidence for their clinical effectiveness is lacking.
These problems are exacerbated by inaccurate labelling of
fatty acid content on six US samples. Mostly registered
monopreparations medicinal products from Finland, Swit-
zerland and Canada, and 12 combination products fulfilled
only pharmacopoeial quality requirement.[14]
Mature saw palmetto fruits yield twice as much lauric
acid than immature fruits; very mature fruits contain more
oleic acid than lauric acid.[2,28] The pattern from the nine
ethanolic preparations showed that the majority of the
manufacturers of the extracts used the same mixture of
immature and mature fruits, and that they were a mixture
from all regions of Florida as the fatty acid pattern varies
significantly between the different regions in Florida.[25] The
only samples that differed from the average fatty acid
content were SP34, SP54 and SP8 that contained more
oleic/linoleic acid than the other test items. This could be
due to using more very mature fruits or that they were from
a single cultivation where the berries contain more oleic
acid. In an unpublished report, Berries from central Florida
displayed a laureate to oleate ratio twice as high compared
to samples from northern Florida.[28] This calls for a more
systematic study of the supply of value chains from produc-
ers to consumers.[29]
Nevertheless, the GC method applied is limited as
only fatty acids can be analysed. Other substances like
β-sitosterol, γ-tocopherol and δ-tocopherols, or β-carotene
that influence symptoms associated with BPH should also
be determined to characterise the saw palmetto products
better. We decided instead of analysing more substances to
use a different approach for further assessment of the
preparations.
1H NMR spectroscopy combined with PCA allows focus-
ing on all with 1H NMR spectroscopy detectable constitu-
ents. In this study, a robust and economical method has
been developed for the 1H NMR spectroscopy analysis of
different dosage forms of saw palmetto products. By using
multivariate analysis, it has been possible to identify major
constituents, statistically group data and critically analyse
the variation in composition of compounds within the
products, but it is unlikely to be a full representation of all
the compounds present in the fruit of Serenoa repens. One
soft gel capsule extract product from America was manufac-
tured using a super-critical fluid extraction process, and this
study has shown that this product exhibits a significant dif-
ference in its metabolomic fingerprint compared with
ethanol extracts. This study has demonstrated that it is pos-
sible to differentiate between saw palmetto samples that
have been extracted using different solvents and extraction
techniques; however, PCA was unable to detect small differ-
ences between extracts that were processed in similar ways
and so may have limitations when detailed comparison of
similar extracts is required.
One of the main problems associated with metabolomics
is that the metabolome consists of a wide range of com-
pounds at very different concentrations and with different
polarities. At present, there is no single solvent capable of
solubilising the whole range of chemical constituents. The
choice of extraction solvent is thus limiting the view on the
metabolome. It is widely accepted that a single analytical
technique will not provide sufficient visualisation of the
metabolome, and therefore, multiple techniques are needed
for a comprehensive view. However, practical reasons can
force us to choose an optimum analytical tool for
metabolomic profiling. Consequently, it may be preferable
to use a wide spectrum chemical analysis technique, which
is rapid, reproducible and stable in time, while needing only
the very basic sample preparation. 1H NMR spectroscopy is
potentially an analytical tool that could meet these require-
ments.[30,31] 1H NMR spectroscopy combined with multi-
variate or pattern recognition techniques is an ideal tool for
large-scale plant metabolomics data collection, and a
number of techniques have now been devised to develop
NMR spectroscopy as a fingerprinting tool for the quality
assessment of crude plant materials.[32] This included differ-
entiation between various batches obtained from the same
supplier, highlighting the potential to use the method for
assessing whether the species’ extract variability versus the
manufacturing process accounts for the variability.[33]
Despite the overall relatively large number of samples
included, the current study was limited by relatively low
number of samples tested for each group of products, but as
larger numbers of samples are added, the statistical analysis
will become more robust and yield better data to cluster
similar products.
The GC analysis provided a means to rapidly assess the
concentration of known fatty acids within the saw palmetto
products. The 1H NMR spectroscopy analysis enabled us to
look at a wider range of chemical compounds and compare
each of the products based on their total extractable
metabolite content.[34] Both methods provided different
information on the content of the products. By using GC
analysis, it was possible to determine that some of the
products contained higher amounts of some fatty acids
associated with adulteration, and the 1H NMR spectroscopy
analysis was able to confirm this. Importantly, 1H NMR
spectroscopy analysis was able to provide some evidence
that certain saw palmetto products were adulterated with
compounds not detected by GC analysis (mainly other
plant oils). Using PCA analysis, it has been possible to
identify groupings within products based on their
metabolomics profile. In the future, using this type of
grouping, it will be possible to set up PCA models for
saw palmetto products that could be used in product devel-
opment, quality assurance and to aid in the detection of
counterfeit products.
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Conclusions
This is the first study comparing 1H NMR-based
metabolomics with an established and already validated
method. Using PCA analysis, it has been possible to identify
groupings within products based on their metabolomics
profile. In the future, using this type of grouping, it will be
possible to set up PCA models for saw palmetto products
that could be used in product development, quality assur-
ance and to aid in the detection of counterfeit products.
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